Navigation Links
New Treatment Combo Better Against Hepatitis C
Date:4/29/2009

Adding antiviral telaprevir increases cure rate, studies show,,,,

WEDNESDAY, April 29 (HealthDay News) -- Adding the antiviral drug telaprevir to standard treatment for hepatitis C increases the cure rate, two new studies show.

Current treatment for hepatitis C (HCV) genotype 1, the most common subtype, is a combination of two drugs, pegylated interferon and ribavirin, given over 48 weeks. This treatment cures less than half of patients and has side effects that make it difficult for some patients to complete the treatment, researchers say. Both reports are published in the April 30 issue of the New England Journal of Medicine.

"Hepatitis C is curable," said the lead researcher of the first study Dr. Jean-Michel Pawlotsky, from the Henri Mondor Hospital, University of Paris, in France. "Currently, 40 to 50 percent of patients infected with HCV genotype 1 can be cured by standard of care, but nothing can be offered to the patients who are unable to eradicate infection on treatment."

For the study, Pawlotsky's team randomly assigned 334 patients with HCV to one of four treatment combinations of telaprevir, peginterferon and ribavirin

The results show that, by using a triple combination of telaprevir, pegylated interferon and ribavirin for 12 weeks, followed by 12 weeks of pegylated interferon and ribavirin, a sustained viral eradication can be achieved in 69 percent of cases, whereas only 46 percent of patients receiving standard of care for 48 weeks achieve a cure, Pawlotsky said.

"This is a breakthrough in HCV therapy," Pawlotsky said. "For the very first time, almost 70 percent cure rates are reached."

These findings open the way to an ongoing phase 3 trial, which could lead to the approval of this combination within the next two years, he said. "The triple combination could become the new standard of care," he noted.

In the second study, Dr. John G. McHutchison, a
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. New Treatment Discovered for Restless Legs Syndrome Improves Sleep
2. Free Treatment for Breast Cancer Available in Pennsylvania
3. Zebrafish offer clues to treatments for motor neurone disease
4. New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
5. Varicose Veins Pose Scary Health Risk; Sufferers Find Solace With Insurance-Covered Treatment at Renaissance Laser and Vein Institute
6. Study finds higher drug co-pays discourage patients from starting treatment
7. A Call to Action: NGOs Working in Blindness Prevention and Treatment Convene Special Forum to Address Gender and Eye Health
8. Turtle Island Oxygen Trust Sponsors Free Hyperbaric Treatments
9. Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group
10. Different treatment options in chronic coronary artery disease
11. Wyeths CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Treatment Combo Better Against Hepatitis C
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... LAUREL, N.J., July 1 MedQuist Inc.,(Pink ... community hospital,located in Westfield, Mass., has selected ... to provide hospital-wide,dictation, transcription and speech recognition ... recognition capability will be,used throughout the hospital ...
... and Bruce Bradley (General,Motors) - to Serve as ... ABIM Foundation,will dedicate its efforts over the next ... and accountability in health care toward the,ultimate goal ... Foundation announced that officers of its Board of,Trustees ...
... WALTHAM, Mass., July 1 Repligen Corporation,(Nasdaq: RGEN ... has been,elected to its Board of Directors. Dr. Goldberg ... School. He is a renowned scientist noted in,particular for ... the mechanism by which most proteins are destroyed in,cells. ...
... fed junk food had higher cholesterol, blood fats into ... News) -- Eating an unhealthy diet during pregnancy may ... cholesterol and blood sugar levels, British researchers report. , ... fed one group of females a diet of processed ...
... Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical ... ... Resources, WALTHAM, Mass., July 1 ... on pharmaceutical and,healthcare issues, finds that a weight neutral oral antidiabetic drug ...
... Health Administrator, Meet Aggressive Hospital Opening Schedule; Eases Ongoing IT ... ... Effort, RIOJA, Spain, July 1 TIBCO Software Inc.,(Nasdaq: ... region of Rioja has deployed its real-time integration,infrastructure. The project at ...
Cached Medicine News:Health News:Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition 2Health News:Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition 3Health News:ABIM Foundation Announces New Focus and Governance 2Health News:ABIM Foundation Announces New Focus and Governance 3Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 3Health News:Mom's Unhealthy Diet May Have Long-Term Impact on Baby 2Health News:A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market 2Health News:Rioja Hospital Uses TIBCO Software to Improve Customer Care and Streamline Operations 2
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... Jan. 15, 2014  Novation, the leading health care supply ... IT value-added reseller (VAR) national contracts that expand its ... services at lower costs. These include manufacturer product and ... initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... a Conference Call on Monday, April 14, at 8:30 a.m. E.T. ... ... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced additional results from its,ongoing ... hypercholesterolemia (FH). In FH patients exposed to,mipomersen for as long as ...
... Researchers from the,Barbara Ann Karmanos Cancer ... adding curcumin or resveratrol to conventional chemotherapy,could ... chemo-resistant colon cancer,cells. The poster presentation was ... (AACR) Annual Meeting in San Diego, CA., ...
Cached Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
... Supplemental Confirmatory (Western Blot): The assay uses ... on their surface. The cells are fixed ... slide. Fixed, uninfected T-cells are provided as ... sample with HIV- I antibodies comes in ...
Bi-phasic peristaltic infusion pump for tumescent work....
... The Klein Pump provides ... requiring tumescent infiltration. Operates on ... off switch with safety Interlock ... Single Spike Tubing, Double Spike ...
... state of the art Aspirator offers ... It can accommodate up to 5 ... eliminating time consuming canister changes. The ... powerful performance with minimal noise. It ...
Medicine Products: